Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran; Department of Nutrition and food hygiene, Faculty of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran; Department of Epidemiology and Biostatistics, Faculty of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Complement Ther Med. 2019 Dec;47:102216. doi: 10.1016/j.ctim.2019.102216. Epub 2019 Oct 19.
Obesity is highly prevalent worldwide. Emerging clinical studies suggest that pre- and pro- biotic formulations may be effective interventions for the management of obesity and associated metabolic complications. The current trial was conducted to assess the effect of synbiotic supplementation on anthropometric indices, glycemic and lipid profile, blood pressure, and psychological status of adults with overweight or obesity.
This randomized double-blind, placebo-controlled trial was conducted on 60 adults with overweight or obesity. Participants were randomly assigned into two groups to receive either synbiotics (n = 30) in form of a 500 mg capsule (containing Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum plus inulin) or placebo (n = 30) for 8 weeks. The level of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FPG), insulin, body weight, body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), stress, anxiety, and depression were measured at the baseline and end of the study.
In total, 59 subjects (39 men and 20 women) completed the present study. A significant between-group decrease in body weight (P = 0.03), TC (P = 0.01), TG (P = 0.02), LDL-C (P = 0.01), stress (P < 0.001), anxiety (P = 0.03), and depression (P = 0.03) was found in the synbiotic group compared to the placebo. However, synbiotics had no significant effect on HDL-C, SBP, DBP, FPG and fasting insulin concentrations, as well the BMI and WC (P < 0.05).
The present study showed that synbiotic supplementation can confer a number of health benefits including improvements in TG, TC, LDL-C, body weight, stress, anxiety, and depression to subjects that are overweight or obesity.
Iranian Registry of Clinical Trials IRCT20180201038585N3.
肥胖症在全球范围内高度流行。新兴的临床研究表明,益生菌和益生元制剂可能是治疗肥胖症和相关代谢并发症的有效干预措施。本试验旨在评估合生元补充剂对超重或肥胖成年人的体重指数、血糖和血脂谱、血压和心理状态的影响。
这是一项随机、双盲、安慰剂对照试验,共纳入 60 名超重或肥胖成年人。参与者被随机分为两组,分别接受合生元(30 人)或安慰剂(30 人)治疗 8 周。合生元以 500mg 胶囊形式(含嗜酸乳杆菌、干酪乳杆菌和双歧杆菌加菊粉)服用。在研究开始和结束时,测量总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FPG)、胰岛素、体重、体重指数(BMI)、腰围(WC)、收缩压(SBP)、舒张压(DBP)、应激、焦虑和抑郁。
共有 59 名受试者(39 名男性和 20 名女性)完成了本研究。与安慰剂组相比,合生元组体重(P=0.03)、TC(P=0.01)、TG(P=0.02)、LDL-C(P=0.01)、应激(P<0.001)、焦虑(P=0.03)和抑郁(P=0.03)显著下降。然而,合生元对 HDL-C、SBP、DBP、FPG 和空腹胰岛素浓度、BMI 和 WC 没有显著影响(P<0.05)。
本研究表明,合生元补充剂可改善超重或肥胖人群的 TG、TC、LDL-C、体重、应激、焦虑和抑郁等多项健康指标。
伊朗临床试验注册中心 IRCT20180201038585N3。